Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | HTT | P42858 | 3/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 2/20 | 0.72 |
| ▸ | RNF4 | P78317 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.57 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7342035 | 0.89 | NPC1 (0.79) | NPC1RAB9AALDH1A1HTTPAX8 | |
| SCHEMBL23518793 | 0.86 | RNF4 (0.85) | NPC1RAB9AALDH1A1HTTPAX8 | |
| SCHEMBL18338252 | 0.85 | RAB9A (1.00) | NPC1RAB9AALDH1A1HTTPAX8 | |
| SCHEMBL27711364 | 0.85 | RAB9A (0.72) | NPC1RAB9AALDH1A1HTTPAX8 | |
| SCHEMBL20857045 | 0.83 | RAB9A (0.69) | NPC1RAB9AALDH1A1HTTPAX8 | |
| SCHEMBL5144037 | 0.83 | NPC1 (0.71) | NPC1RAB9AALDH1A1HTTPAX8 | |
| SCHEMBL5144036 | 0.83 | ALDH1A1 (0.71) | NPC1RAB9AALDH1A1HTTPAX8 | |
| SCHEMBL8181665 | 0.82 | ALDH1A1 (0.70) | NPC1RAB9AALDH1A1HTTPAX8 | |
| SCHEMBL21105957 | 0.82 | RNF4 (0.79) | NPC1RAB9AALDH1A1HTTPAX8 | |
| SCHEMBL1927016 | 0.82 | ALDH1A1 (0.69) | NPC1RAB9AALDH1A1HTTPAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691895-B2 | Thrombopoietin activity modulating compounds and methods | LIGAND PHARMACEUTICALS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080146594-A1 | THROMBOPOIETIN ACTIVITY MODULATING COMPOUNDS AND METHODS | Ligand Pharmaceutical, Inc. (US) | 2008-06-19 | — | — | US | disclosed |
| US-20080103190-A1 | THROMBOPOIETIN ACTIVITY MODULATING COMPOUNDS AND METHODS | LIGAND PHARMACEUTICALS, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-7314887-B2 | 3'-{N'-[1-(3,4-Dimethyl-phenyl)-2-oxo-1,2-dihydro-indol-3-ylidene]-hydrazino}-2'-hydroxy-biphenyl-3-carboxylic acid; recptor agonist | LIGAND PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314887-B2 | 3'-{N'-[1-(3,4-Dimethyl-phenyl)-2-oxo-1,2-dihydro-indol-3-ylidene]-hydrazino}-2'-hydroxy-biphenyl-3-carboxylic acid; recptor agonist | LIGAND PHARMACEUTICALS, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | IONIX PHARMACEUTICALS LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-1660454-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | Vernalis (R&D) Limited (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005005392-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | IONIX PHARMACEUTICALS LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
| US-5223529-A | Nervous system and gastrointestinal disorders | RHONE-POULENC SANTE (FR) | 1993-06-29 | — | — | US | disclosed |
| EP-0115954-B1 | BICYCLOOCTANE DERIVATIVES AND THEIR PRODUCTION AND USE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-08-19 | — | — | EP | disclosed |
| US-4680307-A | Carbacyclin analogs | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-07-14 | — | — | US | disclosed |
| EP-0115954-A2 | Bicyclooctane derivatives and their production and use | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-08-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146594-A1 | THROMBOPOIETIN ACTIVITY MODULATING COMPOUNDS AND METHODS | MPL, THPO, TEK | NPC1 2423/4885RAB9A 2341/4885ALDH1A1 3117/4885 |
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | SCN1B, SCN1A, SCN10A | NPC1 608/4885RAB9A 3011/4885ALDH1A1 489/4885 |
| US-20080103190-A1 | THROMBOPOIETIN ACTIVITY MODULATING COMPOUNDS AND METHODS | MPL, THPO, TEK | NPC1 2806/4885RAB9A 2434/4885ALDH1A1 3733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.